11-01-04

IFW

PC25050A Correction of Inventorship in an Application



Certificate of Mailing (37 C.F.R. §1.10):
I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (EV 386659498 US) in an envelope addressed to: Mail Stop: OIPE, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 29TH day of October 2004.

s/_____ Pamela Hollander

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: **Qiyue HU et al.**

Serial No.: 10/699,068

Confirmation No.: 1367

Filed: October 30, 2003

For: HIV INTEGRASE INHIBITORS,

PHARMACEUTICAL COMPOSITIONS, AND

METHODS FOR THEIR USE

Group Art Unit: 1625

Examiner: EveyIn Huang

Honorable Commissioner For Patents P.O. Box 1450 Alexandria, VA 22313-1450

REQUEST FOR CORRECTION OF INVENTORSHIP IN AN APPLICATION UNDER 37 CFR 1.48 (a)(1)

Applicants request correction of the Inventorship in the above-referenced application pursuant to 37 CFR 1.48(a). Inventor Ted William JOHNSON was inadvertently omitted from the Application. This error occurred without deceptive intent, on his part.

Pursuant to 37 CFR 1.48(a), Applicant attaches the following documents:

- 1. A statement under C.F.R. §1.48(a)(2) from each person being added as an inventor that the error in inventorship occurred without deceptive intention on his part;
- 2. An oath or declaration required by §1.67 (a)(2);
- 3. The processing fee set forth in §1.17(i); and
- 4. The written consent of the assignee.

If any other fees are due in connection with the filing of this response please charge all necessary fees to the deposit account 500329.

Respectfully submitted,

Date: October 29, 2004

Attorney For Applicants
Registration No. 47,995

Tolus

Agouron Pharmaceuticals, Inc./A Pfizer Company Patent Department 10777 Science Center Drive San Diego, California 92121

Phone: (858) 638-3877 Fax: (858) 678-8233

PC25050A Document Filed Correction of Inventorship in an Application



Certificate of Mailing (37 C.F.R. §1.10).
I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (EV 386659498 US) in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 29 th day of October 2004.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: Qiyue HU et al.

Serial No.: 10/699,068

Confirmation No.: 1367

Filed: October 30, 2003

For: HIV INTEGRASE INHIBITORS,

PHARMACEUTICAL COMPOSITIONS, AND

METHODS FOR THEIR USE

Date: October 28, 2004

Group Art Unit: 1625

Examiner: EveyIn Huang

Honorable Commissioner For Patents P.O. Box 1450 Alexandria, VA 22313-1450

CORRECTION OF INVENTORSHIP IN AN APPLICATION 37 CFR 1.48 (a)(2)

I, Ted William Johnson, was inadvertently omitted as an inventor in United States Patent Application No. 10/699,068, filed October 30, 2004. This error in inventorship occurred without deceptive intention on my part.

Respectfully submitted,

Ted William JOHNSON

PTO/SB/96 (06-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)
Applicant/Patent Owner:Agouron Pharmaceuticals, Inc.
Application No./Patent No.: 10/699,068 Filed/sexexDate: October 30, 2003
Entitled: HIV INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR
THEIR USE. Agouron Pharmaceuticals. Inc., a Corporation (Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)
states that it is: 1. ☑ the assignee of the entire right, title, and interest; or
2. In an assignee of less than the entire right, title and interest. The extent (by percentage) of its ownership interest is ——————————————————————————————————
A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.
OR
B. [] A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:
1. From: — To: —
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.
2. From:
The document was recorded in the United States Patent and Trademark Office at
Reel, Frame, or for which a copy thereof is attached.
3. From: To:
The document was recorded in the United States Patent and Trademark Office at
Reel, Frame, or for which a copy thereof is attached.
[] Additional documents in the chain of title are listed on a supplemental sheet.
] Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (<i>i.e.</i> , a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.
October 6, 2004 Bryan C. Zielinski
Date Typed or printed name
858 622-8864
Telephone number Signature
Assistant Secretary
Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/17 (10-03)
Approved for use through 09/22/2006. OMB 0651-0032
U.S. Patent and Trademark Office;U.S. DEPARTMENT OFCOMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number Complete if Known **TRANSMITTAL** 10/699,068 **Application Number** for FY 2005 October 30, 2003 Filing Date First Named Inventor Qiyue HU Effective 10/01/2003. Patent fees are subject to annual revision. To be assigned. **Examiner Name** 1614 Applicant claims small status. See 37 CFR 1.27 Art Unit Attorney Docket No. PC25050A **Total Amount of Payment** FEE CALCULATION (continued) METHOD OF PAYMENT (check all that apply) 3. ADDITIONAL FEES ☐ Money ☐ Other ☐ None ☐ Check ☐ Credit Card Large Entity **Small Entity** Fee Paid **Fee Description** Fee Fee Deposit Account: Code Code (\$) 1051 130 2051 65 Surcharge - late fee or oath Deposit 500329 Account Number 1052 50 2052 25 Surcharge-late filing fee or cover sheet Agouron Pharmaceuticals, Inc. Deposit Account Name Non-English specification 1053 130 1053 130 The Director is authorized to: (check all that apply) For filing a request for Ex Parte reexamination 2,520 1812 2 520 1812 ☐ Charge fee(s) indicated below Credit any overpayments Requesting publication of SIR prior to 1804 920* 1804 920* Charge any additional fee(s) or any underpayment of fee(s) Examiner action Requesting publication of SIR after 1805 1,840* 1805 1,840* ☐ Charge fee(s) indicated below, except for the filing fee Examiner action to the above-identified deposit account. Extension for reply within first month 1251 110 2251 55 **FEE CALCULATION** 2252 215 Extension for reply within second month 1252 430 1. BASIC FILING FEE Extension for reply within third month 1253 980 2253 490 Small Entity Large Entity 2254 Extension for reply within fourth month 1254 1,530 765 Fee Fee Code (\$) Code (\$) Fee Description Fee Paid 1,040 Extension for reply within fifth month 2001 395 Utility filing fee 1255 2,080 2255 1001 790 2401 170 Notice of Appeal 2002 175 Design filing fee 1401 340 350 1002 Filing a brief in support of an appeal 1402 340 2402 170 550 2203 275 Plant filing fee 1003 Request for oral hearing 1403 300 2403 150 Reissue filing fee 1004 790 2004 395 Petition to institute a public use proceeding 1451 1.510 1451 1.510 160 2005 80 filing fee 1005 2452 55 Petition to revive unavoidable 1452 110 665 Petition to revive - unintentional 1,330 2453 Subtotal (1)s 1453 685 Utility issue fee (or reissue) 1,370 2501 1501 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE Design issue fee Fee Paid 1502 480 2502 245 Extra Claims Fee from below 660 2503 330 Plant issue fee 1503 **Total Claims** - 20** = Petitions to the Director 1460 130 1460 130 Independent - 3 = Processing fee under 37 CFR 1.17(q) 1807 50 1807 50 Multiple Dependent Submission of Information Disclosure Strnt 1806 180 1806 180 Large Entity Small Entity Recording each patent assignment per 8021 40 8021 40 Fee Description Fee (\$) property (times number of properties) Code (\$) Code 395 Filing a submission after final rejection 2809 1809 790 Claims in excess of 20 1202 18 2202 (37 ČFR 1.129(a)) For each additional invention to be 2810 395 1810 790 Independent claims in excess of 3 2201 1201 88 examined (37 CFR 1.129(b))

Request for Continued Examination (RCE) 395 Multiple dependent claim, if not paid 1801 790 2801 1203 300 2203 150 Request for expedited examination 1802 900 1802 900 **Reissue independent claims over 1204 88 2204 of a design application original patent **Reissue independent claims over original 1205 18 2205 Other Fee (specify) Processing Fee 1.17(i) patent (\$) Subtotal (3) (\$) 130. *Reduced by Basic Filing Fee Paid - **or number previously paid, if greater, For Reissues, see above

(Complete if applicable) SUBMITTED BY 858 638-3877 47,995 Telephone Jeffrey H. Tidwell Registration No. Name (Printed/Type) (Attorney Agent)

Signature Warning/Uro mation on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and /or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-pto-9199 and select option2.